☆ 4.3 Editorial Material

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study

JOURNAL OF THORACIC DISEASE (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC DISEASE
Volume 10, Issue -, Pages S1108-S1112

Publisher

AME PUBLISHING COMPANY
DOI: 10.21037/jtd.2018.03.180

Keywords

-

Categories

Respiratory System

Funding

  1. AstraZeneca
  2. Ono Pharmaceutical Co., Ltd.
  3. Chugai Pharmaceutical Co., Ltd.
  4. Eli Lilly
  5. Novartis
  6. Taiho Pharmaceutical Co., Ltd.
  7. Nippon Boehringer Ingelheim
  8. Pfizer
  9. Bristol-Meyers Squibb
  10. Clovis Oncology
  11. MSD
  12. Kissei
  13. Eisai
  14. Takeda Pharmaceutical Co., Ltd.
  15. Dainippon Sumitomo Pharma
  16. Abbvie
  17. Merck Serono
  18. Kyowa Hakko Kirin
  19. Daiichi Sankyo
  20. Astellas
  21. Ignyta
  22. Servier

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.